TwitterLinkedInYoutubeSlideshareflickrIFPMA - Global Health Matters - BlogRSS

International Federation of Pharmaceutical Manufacturers & Associations

  • The IFPMA believes that investments in prevention, awareness and education are critical and cost-effective measures for alleviating the burden of NCDs.
  • The IFPMA calls for a multi-stakeholder approach and its Members are committed to reducing the burden of NCDs, working alongside other key stakeholders in a growing range of prevention, awareness and healthcare capacity-building initiatives.
  • IFPMA Members are actively engaged in multiple partnerships to help address NCDs in low and middle income countries, providing support, education, training, awareness, screening, capacity building, and access to communities in need. As responsible employers, IFPMA Members have also implemented worksite wellness policies for hundreds of thousands of employees around the world.
  • The IFPMA supports the WHO’s Global Action Plan for the Prevention and Control of NCDs and is engaged in the implementation of its relevant outlined objectives.


It is estimated that half of the deaths caused by NCDs are preventable. Prevention can be achieved through increased health literacy, awareness and simple behavioral changes aimed at reducing common risk factors. As the increased prevalence of NCDs poses a mounting challenge to healthcare systems worldwide and to public and private finances, prevention represents a cost-effective solution for alleviating the economic burden of such diseases. Reducing mortality and morbidity through increased investment in prevention programs will contribute to higher economic growth and allow limited resources to be focused efficiently on patients most in need.

Combating NCDs should be a shared commitment: it requires effective, multi-stakeholder strategies at the global, regional and national levels that are fully integrated into healthcare systems and extend beyond the traditional health sector. Governments must help to prevent and manage these diseases effectively; in particular, by strengthening health care systems. Other stakeholders, such as health professionals and civil society, can also play a major role in increasing awareness and education, improving early detection and disease surveillance, and facilitating implementation of prevention programs. The research-based pharmaceutical industry plays a key role in discovering new medicines for both prevention and treatment of NCDs.

Non-Communicable Diseases (NCDs), such as cancer, diabetes, cardiovascular and respiratory diseases, are the leading cause of death and illness worldwide. Success in the fight against infectious diseases, and rising living standards and the changes in lifestyle that accompany – unhealthy diet, tobacco use, and so on – have led to a rising proportion of global deaths accounted for by NCDs. Traditionally seen as diseases of the rich world, developing countries now account for nearly 50% of the global NCD burden . NCDs are a growing health and economic challenge for both rich and poor countries.